-
公开(公告)号:US20110213143A1
公开(公告)日:2011-09-01
申请号:US13126685
申请日:2009-10-28
申请人: Hideaki Amada , Daisuke Matsuda , Masahiro Bohno , Shiuji Saito , Ayako Bohno
发明人: Hideaki Amada , Daisuke Matsuda , Masahiro Bohno , Shiuji Saito , Ayako Bohno
IPC分类号: C07D487/04 , C07D471/04 , C07D498/04 , C07D471/14
CPC分类号: C07D471/04 , C07D487/04
摘要: Provided are compounds having superior TAFIa inhibitory activity. Specifically, there are provided compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: wherein A is a benzene ring or a pyridine ring; X is the formula —(CH2)—, the formula —(CH2)2—, an oxygen atom, a nitrogen atom or a single bond; Y is the formula —(CH2)3—NH—R3, the formula —(CH2)4—NH—R3 or a 2-aminopyridyl group; R3 is a hydrogen atom, a C1-6 alkyl group, or the formula —CO2R4; R4 is a C1-6 alkyl group, the formula —CHR5OC(O)R6, or a substituent having the structure represented by the following formula Ia; R5 is a C1-6 alkyl group; R6 is a C1-6 alkyl group, a C3-8 cycloalkyl group, or a phenyl group; R7 is a C1-6 alkyl group or a phenyl group; R1 is a hydrogen atom, a halogen atom, a C1-4 alkyl group substituted by 1-3 halogen atoms, a C1-10 alkyl group, a C1-8 alkoxy group, a C3-8 cycloalkyl group, a C3-8 cycloalkoxy group, a C4-14 cycloalkylalkyl group, or a phenyl group; R2 is CO2R8, or a tetrazolyl group; R8 is a hydrogen atom, a C1-10 alkyl group, or a substituent having the structure represented by the following formula Ib or Ic; m and n are each an integer of zero or one.
摘要翻译: 提供具有优异TAFIa抑制活性的化合物。 具体地,提供由下式(I)表示的化合物或其药学上可接受的盐:其中A是苯环或吡啶环; X是式 - (CH 2) - ,式 - (CH 2)2 - ,氧原子,氮原子或单键; Y是式 - (CH2)3-NH-R3,式 - (CH2)4-NH-R3或2-氨基吡啶基; R 3是氢原子,C 1-6烷基或式-CO 2 R 4; R4是C1-6烷基,式-CHR5OC(O)R6或具有由下式Ia表示的结构的取代基; R5是C1-6烷基; R6是C1-6烷基,C3-8环烷基或苯基; R7是C1-6烷基或苯基; R1是氢原子,卤素原子,被1-3个卤素原子取代的C1-4烷基,C1-10烷基,C1-8烷氧基,C3-8环烷基,C3-8环烷氧基 基团,C4-14环烷基烷基或苯基; R2是CO2R8或四唑基; R8是氢原子,C1-10烷基或具有由下式Ib或Ic表示的结构的取代基; m和n分别为0或1的整数。
-
公开(公告)号:US07678810B2
公开(公告)日:2010-03-16
申请号:US10591614
申请日:2005-03-04
申请人: Masakazu Sato , Yuko Matsunaga , Hajime Asanuma , Hideaki Amada , Takeshi Koami , Tetsuo Takayama , Tetsuya Yabuuchi , Fumiyasu Shiozawa , Hironori Katakai , Hiroki Umemiya , Akiko Ikeda
发明人: Masakazu Sato , Yuko Matsunaga , Hajime Asanuma , Hideaki Amada , Takeshi Koami , Tetsuo Takayama , Tetsuya Yabuuchi , Fumiyasu Shiozawa , Hironori Katakai , Hiroki Umemiya , Akiko Ikeda
IPC分类号: A61K31/4439 , C07D277/62 , C07D317/48
CPC分类号: A61K8/49 , A61Q7/00 , C07D417/04 , C07D417/06 , C07D417/14
摘要: A thiazolylimidazole derivative represented by the formula or a pharmaceutically acceptable salt thereof, and an ALK5 inhibitor, an therapeutic agent for alopecia or a hair growth agent having the above as an active ingredient, wherein: X1 and X2 are different from each other and represent a sulfur atom or a carbon atom; R1 represents a phenyl group; a substituted phenyl group; a phenyl group condensed with a hetero aromatic ring; a pyridyl group; or a pyridyl group condensed with a hetero aromatic ring; R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkyl group having 1 to 6 carbon atoms substituted with 1 to 5 halogen atoms, an alkoxy group having 1 to 6 carbon atoms, an alkanoyl group having 1 to 5 carbon atoms, or a hydroxyalkyl group having 1 to 6 carbon atoms, A represents a group which is represented by the formula. The present invention provides an inhibitory substance against ALK5 which is a TGF-β type I receptor and provides a hair growth stimulant or a hair growth agent based on its novel activities.
摘要翻译: 由下式表示的噻唑咪唑衍生物或其药学上可接受的盐,以及ALK5抑制剂,秃发治疗剂或具有上述作为活性成分的毛发生长剂,其中:X1和X2彼此不同,表示 硫原子或碳原子; R1表示苯基; 取代的苯基; 与杂芳环稠合的苯基; 吡啶基; 或与杂芳环稠合的吡啶基; R2表示氢原子,卤素原子,碳原子数1〜6的烷基,碳原子数1〜5的碳原子数1〜5的烷基,碳原子数1〜6的烷氧基,烷氧基 具有1至5个碳原子,或具有1至6个碳原子的羟烷基,A表示由下式表示的基团。 本发明提供一种抗ALK5抑制物质,其为TGF- I型受体,并且基于其新的活性提供毛发生长兴奋剂或毛发生长剂。
-
公开(公告)号:US20070154428A1
公开(公告)日:2007-07-05
申请号:US10591614
申请日:2005-03-04
申请人: Masakazu Sato , Yuko Matsunaga , Hajime Asanuma , Hideaki Amada , Takeshi Koami , Tetsuo Takayama , Tetsuya Yabuuchi , Fumiyasu Shiozawa , Hironori Katakai , Hiroki Umemiya , Akiko Ikeda
发明人: Masakazu Sato , Yuko Matsunaga , Hajime Asanuma , Hideaki Amada , Takeshi Koami , Tetsuo Takayama , Tetsuya Yabuuchi , Fumiyasu Shiozawa , Hironori Katakai , Hiroki Umemiya , Akiko Ikeda
IPC分类号: A61K8/49 , A61K31/5377 , A61K31/496 , A61K31/4709 , A61K31/454 , A61K31/427 , C07D417/02
CPC分类号: A61K8/49 , A61Q7/00 , C07D417/04 , C07D417/06 , C07D417/14
摘要: A thiazolylimidazole derivative represented by the formula or a pharmaceutically acceptable salt thereof, and an ALK5 inhibitor, an therapeutic agent for alopecia or a hair growth agent having the above as an active ingredient, wherein: X1 and X2 are different from each other and represent a sulfur atom or a carbon atom; R1 represents a phenyl group; a substituted phenyl group; a phenyl group condensed with a hetero aromatic ring; a pyridyl group; or a pyridyl group condensed with a hetero aromatic ring; R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkyl group having 1 to 6 carbon atoms substituted with 1 to 5 halogen atoms, an alkoxy group having 1 to 6 carbon atoms, an alkanoyl group having 1 to 5 carbon atoms, or a hydroxyalkyl group having 1 to 6 carbon atoms, A represents a group which is represented by the formula. The present invention provides an inhibitory substance against ALK5 which is a TGF-β type I receptor and provides a hair growth stimulant or a hair growth agent based on its novel activities.
摘要翻译: 由下式表示的噻唑咪唑衍生物或其药学上可接受的盐,以及ALK5抑制剂,秃发治疗剂或具有上述作为活性成分的毛发生长剂,其中:X 1和X 2 2个彼此不同,表示硫原子或碳原子; R 1表示苯基; 取代的苯基; 与杂芳环稠合的苯基; 吡啶基; 或与杂芳环稠合的吡啶基; R 2表示氢原子,卤素原子,具有1至6个碳原子的烷基,具有1至5个被1至5个卤素原子取代的碳原子的烷基,具有1个 至6个碳原子,具有1至5个碳原子的烷酰基或具有1至6个碳原子的羟烷基,A表示由下式表示的基团。 本发明提供了抗ALK5的抑制物质,其为TGF-β1型受体,并且基于其新的活性提供毛发生长刺激剂或毛发生长剂。
-
公开(公告)号:US07078400B2
公开(公告)日:2006-07-18
申请号:US10609547
申请日:2003-07-01
申请人: Masakazu Sato , Noriyuki Miyata , Takaaki Ishii , Yuko Kobayashi , Hideaki Amada
发明人: Masakazu Sato , Noriyuki Miyata , Takaaki Ishii , Yuko Kobayashi , Hideaki Amada
IPC分类号: A61P7/02
CPC分类号: A61K31/155 , A61K31/166 , A61K31/18 , A61K31/245 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/352 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4453 , A61K31/45 , A61K31/472 , A61K31/502 , A61K31/505 , A61K31/522 , A61K31/5375 , C07C311/21 , C07C311/46 , C07C317/40 , C07C323/12 , C07C323/19 , C07C323/41 , C07C323/52 , C07C323/65 , C07C335/26 , C07C2601/08 , C07C2601/14
摘要: The present invention relates to an inhibitor for production of 20-hydroxyeicosatetraenoic acid, comprising, as an effective ingredient, specific hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof. The inhibitors according to the present invention are useful as therapeutic agents for kidney diseases, cerebrovascular diseases, or circulatory diseases.In addition, the present invention also provides novel hydroxyformamidine derivatives or pharmaceutically-acceptable salts thereof.
摘要翻译: 本发明涉及一种用于制备20-羟基二十碳烯四烯酸的抑制剂,其包含作为有效成分的特定羟基甲脒衍生物或其药学上可接受的盐。 根据本发明的抑制剂可用作肾脏疾病,脑血管疾病或循环系统疾病的治疗剂。 此外,本发明还提供新的羟基甲脒衍生物或其药学上可接受的盐。
-
公开(公告)号:US06864254B1
公开(公告)日:2005-03-08
申请号:US09869103
申请日:2000-11-01
申请人: Masakazu Sato , Noriyuki Miyata , Takaaki Ishii , Yuko Kobayashi , Hideaki Amada
发明人: Masakazu Sato , Noriyuki Miyata , Takaaki Ishii , Yuko Kobayashi , Hideaki Amada
IPC分类号: A61K31/155 , A61K31/166 , A61K31/18 , A61K31/245 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/352 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4453 , A61K31/45 , A61K31/472 , A61K31/502 , A61K31/505 , A61K31/522 , A61K31/5375 , C07C311/21 , C07C311/46 , C07C317/40 , C07C323/12 , C07C323/19 , C07C323/41 , C07C323/52 , C07C323/65 , C07C335/26 , A81K31/155
CPC分类号: A61K31/155 , A61K31/166 , A61K31/18 , A61K31/245 , A61K31/275 , A61K31/341 , A61K31/343 , A61K31/351 , A61K31/352 , A61K31/357 , A61K31/36 , A61K31/381 , A61K31/40 , A61K31/403 , A61K31/4035 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/4245 , A61K31/426 , A61K31/428 , A61K31/429 , A61K31/433 , A61K31/44 , A61K31/4402 , A61K31/445 , A61K31/4453 , A61K31/45 , A61K31/472 , A61K31/502 , A61K31/505 , A61K31/522 , A61K31/5375 , C07C311/21 , C07C311/46 , C07C317/40 , C07C323/12 , C07C323/19 , C07C323/41 , C07C323/52 , C07C323/65 , C07C335/26 , C07C2601/08 , C07C2601/14
摘要: An inhibitor for 20-hydroxyeicosatetraenoic acid production which comprises as the active ingredient a specific hydroxyformamidine derivative or a pharmacologically acceptable salt thereof. It is useful especially as a remedy for kidney diseases, cerebrovascular diseases, or circulatory diseases. The novel hydroxyformamidine derivative or pharmacologically acceptable salt thereof is also provided.
摘要翻译: 一种20-羟基二十碳烯四烯酸生产抑制剂,其包含作为活性成分的特定羟基甲脒衍生物或其药理学上可接受的盐。 特别是作为肾脏疾病,脑血管疾病或循环系统疾病的补救措施是有用的。 还提供了新的羟基甲脒衍生物或其药理学上可接受的盐。
-
公开(公告)号:US07214714B2
公开(公告)日:2007-05-08
申请号:US10475869
申请日:2002-04-26
申请人: Masakazu Sato , Noriyuki Miyata , Takaaki Ishii , Yuko Matsunaga , Hideaki Amada
发明人: Masakazu Sato , Noriyuki Miyata , Takaaki Ishii , Yuko Matsunaga , Hideaki Amada
IPC分类号: A61K31/136 , A61K31/402 , C07C259/14 , C07D207/20 , C07D211/00 , C07D213/00 , C07D215/00 , C07D241/00 , C07D295/00 , C07D491/00
CPC分类号: C07D213/75 , A61K31/136 , A61K31/402 , A61K31/4418 , A61K31/451 , A61K31/4525 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/5375 , A61K31/54 , A61K31/55 , C07C259/14 , C07D207/20 , C07D211/22 , C07D211/46 , C07D211/60 , C07D211/62 , C07D211/70 , C07D213/74 , C07D217/04 , C07D295/13 , C07D295/135 , C07D295/15 , C07D401/04 , C07D491/10
摘要: A hydroxyformamidine compound represented by the following formula or a pharmaceutically acceptable salt thereof [wherein R1 represents a substituted morpholino group, a substituted piperidino group, a piperazin-1-yl group, a substituted piperazin-1-yl group, a thiomorpholin-1-yl group, a perhydroazepin-1-yl group, a perhydroazocin-1-yl group, a tetrahydropyridin-1-yl group, a pyrrolin-1-yl group, etc.; X represents a nitrogen atom or a group represented by CR5; and R2 to R5 are the same or different and each represents a hydrogen atom, a C1-4 alkyl group, a C1-4 alkoxy group, a trifluoromethyl group or a halogen atom.] There is provided a drug which inhibits an enzyme producing 20-HETE participating in a contracting or dilating action for microvessels and an inducing action for cell proliferation in main organs such as kidney and cerebrovascular vessels.
摘要翻译: 由下式表示的羟基脒化合物或其药学上可接受的盐[其中R 1表示取代的吗啉代基,取代的哌啶子基,哌嗪-1-基,取代的哌嗪-1-基, 吡咯啉-1-基,四氢吡啶-1-基,吡咯啉-1-基,四氢吡啶-1-基,四氢吡啶-1-基,四氢吡啶-1-基,吡咯啉-1-基等。 X表示氮原子或由CR 5表示的基团; R 5和R 5相同或不同,各自表示氢原子,C 1-4烷基,C 1-4烷基, SUB 1-4个烷氧基,三氟甲基或卤素原子。]提供了抑制参与微血管的收缩或扩张作用的20-HETE的酶和细胞增殖诱导作用的药物 在主要器官如肾脏和脑血管血管。
-
-
-
-
-